ORX — Orexo AB Share News
0.000.00%
Last trade - 00:00- SEK850.39m
- SEK471.19m
- SEK26.00m
Brief: Orexo's Adrenaline Product Ox640 Receives First European Patent
Brief: Orexo Q2 EBITDA Loss Widens To SEK 32.5 Mln
Brief: Orexo's Nasal Adrenaline Rescue Medication OX640 Enters Clinical Development
Brief: Orexo Q1 EBITDA Swinga To Profit Of SEK 2.8 Mln
Brief: Orexo Appoints Fredrik Järrsten As New CFO
Brief: Orexo's Zubsolv Added To NY State Medicaid Mat Preferred Drug List
Brief: Orexo Develops A Nasal Adrenaline Medication
Brief: Orexo Announces Positive Results From Pivotal Trial For Its Leading Pharmaceutical Pipeline Asset OX124
Brief: Orexo Q3 EBITDA Loss At SEK 47.4 Mln
Brief: Orexo Flagship Pharmaceutical Pipeline Asset OX124 Enters Pivotal Trial
Brief: Orexo Q2 EBITDA Loss Widens To SEK 41.1 Mln
Brief: Orexo Signs Commercial Partnership Agreement With Sober Grid
Brief: Orexo: USPTO Issues Another Two Patents Relating To ZUBSOLV
Brief: Orexo Q1 EBITDA Swings To Loss Of SEK 23.9 Mln
Brief: Orexo Gets U.S. Patent for Zubsolv
Brief: Orexo Publishes Prospectus And Applies For Admission To Trading Of Corporate Bonds
Brief: Orexo Starts Collaboration With ApexB.io And Magellan Rx Management
Brief: Orexo Calls For Redemption Of Outstanding Bonds, Gets Temporary Waiver
Brief: Orexo Says Successfully Issued Senior Unsecured Callable Floating Rate Bonds